AB-201

DRUG2 trials

Sponsors

Artiva Biotherapeutics, Inc., GC Cell Corporation

Conditions

Breast CancerGastric CancerGastroesophageal Junction Adenocarcinoma

Phase 1

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

WithdrawnNCT05678205

Artiva Biotherapeutics, Inc.Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

Start: 2023-08-01End: 2027-04-30Updated: 2025-07-30

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

WithdrawnNCT06341647

GC Cell CorporationBreast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

Start: 2024-10-31End: 2029-02-28Updated: 2025-01-24